CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...
Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...
Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...
Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, ...
The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, ...
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...
The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...
Breyanzi, a CAR-T cell therapy, shows promise for relapsed or refractory CLL and SLL, achieving a 47% response rate and 18% complete remission rate. CAR-T therapy modifies patient T cells to target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results